addison semaglutide weight loss Medical Denver | Weight Loss Programs Consumers must be protected from

Semaglutide for Fat Loss | STEP Program Data Semaglutides FDA approval for weight loss and chronic weight management was based on the results of phase-3 trials conducted as a part of an ongoing clinical development program called STEP (Semaglutide Treatment Effect in People with Obesity), sponsored by semaglutide's patent holder Novo Nordisk [13]

Primary Handling Editor: Christoph Schmitt, in collaboration with the Nature Metabolism team

Before and after photos show progress

The trick is starting slow, finding the right dose, and checking in with your provider if anything feels off

Latest Clinical Data on Higher Doses The 2025 STEP UP phase 3b trial evaluated semaglutide at both 7.2 mg and 2.4 mg weekly doses versus placebo in people with obesity who did not have diabetes

Soluble fibre dissolves into a gel, which coats and softens stool